These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 9306432

  • 1. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
    [Abstract] [Full Text] [Related]

  • 2. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as chemosensitizer: mechanistic studies. II.
    Papadopoulou MV, Rosenzweig HS, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1998; 10(3):163-73. PubMed ID: 9700727
    [Abstract] [Full Text] [Related]

  • 3. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
    [Abstract] [Full Text] [Related]

  • 4. THNLA-1: a DNA-targeted bioreductive agent as chemosensitizer in vitro and in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    In Vivo; 1996; 10(1):49-57. PubMed ID: 8726811
    [Abstract] [Full Text] [Related]

  • 5. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
    Papadopoulou MV, Bloomer WD.
    Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
    Papadopoulou MV, Ji M, Khan SH, Bloomer WD.
    Oncol Res; 1999 Jul; 11(8):345-57. PubMed ID: 10803738
    [Abstract] [Full Text] [Related]

  • 7. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Oncol Res; 2003 Jul; 13(12):561-6. PubMed ID: 12899246
    [Abstract] [Full Text] [Related]

  • 8. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1.
    Papadopoulou MV, Rosenzweig HS, Doddi M, Bloomer WD.
    Oncol Res; 1994 Jul; 6(9):439-48. PubMed ID: 7703530
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms involved in the potentiation of paclitaxel or 5-fU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro.
    Papadopoulou MV, Ji X, Bloomer WD.
    Anticancer Res; 2005 Jul; 25(3B):2161-70. PubMed ID: 16158959
    [Abstract] [Full Text] [Related]

  • 10. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E.
    Cancer Res; 1989 Nov 01; 49(21):5994-8. PubMed ID: 2790813
    [Abstract] [Full Text] [Related]

  • 11. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV, Ji M, Rao MK, Bloomer WD.
    Oncol Res; 2001 Nov 01; 12(8):325-33. PubMed ID: 11589303
    [Abstract] [Full Text] [Related]

  • 12. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
    Papadopoulou MV, Bloomer WD.
    In Vivo; 2007 Nov 01; 21(2):175-80. PubMed ID: 17436565
    [Abstract] [Full Text] [Related]

  • 13. In vitro evaluation of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-trifluoromethylquinoline hydrochloride (NLTQ-1), a new bioreductive agent as a hypoxia marker by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV, Pouremad R, Rao MK, Ji M, Bloomer WD.
    In Vivo; 2001 Nov 01; 15(5):365-71. PubMed ID: 11695231
    [Abstract] [Full Text] [Related]

  • 14. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
    Papadopoulou MV, Ji M, Bloomer WD.
    Anticancer Res; 2006 Nov 01; 26(5A):3253-8. PubMed ID: 17094437
    [Abstract] [Full Text] [Related]

  • 15. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET, Kelley M, Rockwell S.
    Cancer Chemother Pharmacol; 2004 Jan 01; 53(1):43-50. PubMed ID: 14574460
    [Abstract] [Full Text] [Related]

  • 16. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro.
    Melvik JE, Pettersen EO.
    Radiat Res; 1988 Jun 01; 114(3):489-99. PubMed ID: 3375438
    [Abstract] [Full Text] [Related]

  • 17. Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.
    Papadopoulou MV, Ji X, Bloomer WD.
    J Exp Ther Oncol; 2006 Jun 01; 5(4):261-72. PubMed ID: 17024967
    [Abstract] [Full Text] [Related]

  • 18. NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.
    Papadopoulou MV, Ji M, Bloomer WD.
    Int J Radiat Oncol Biol Phys; 1998 Nov 01; 42(4):775-9. PubMed ID: 9845094
    [Abstract] [Full Text] [Related]

  • 19. Radiosensitizing and toxic properties of quinoline and nitroquinoline complexes of platinum [PtCl2(NH3)quinoline].
    Skov KA, Adomat H, Doedee M, Farrell N.
    Anticancer Drug Des; 1994 Apr 01; 9(2):103-17. PubMed ID: 8166927
    [Abstract] [Full Text] [Related]

  • 20. Hypoxia-selective nitrobenzyloxycarbonyl derivatives of 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazines.
    Shyam K, Penketh PG, Shapiro M, Belcourt MF, Loomis RH, Rockwell S, Sartorelli AC.
    J Med Chem; 1999 Mar 11; 42(5):941-6. PubMed ID: 10072691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.